Medical Condition News

RSS

Coronary artery disease patients with high BMI may face higher risk of death

One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.

3 May 2011

Eurotrans-Bio awards 1.1 million grant to MDxHealth, NovioGendix for bladder cancer program

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that together with partner NovioGendix B.V., a molecular diagnostics company spun out from Radboud University Nijmegen Medical Centre, the Netherlands, has received a USD 1.1 million grant from Eurotrans-Bio to progress its bladder cancer program.

3 May 2011

Beta amyloid may inhibit specific cell motors and contribute to memory loss

A protein associated with Alzheimer's disease clogs several motors of the cell transport machinery critical for normal cell division, leading to defective neurons that may contribute to the memory-robbing disease, University of South Florida researchers report.

3 May 2011

Guided Therapeutics launches LuViva Advanced Cervical Scan

Guided Therapeutics, Inc., unveiled the new name and new industrial design for its non-invasive and painless test for the early detection of cervical precancer.

3 May 2011

Doctors should consider catheterization for diagnosing children with heart defects: AHA

Doctors should consider using catheterization as a treatment tool in addition to its established role in diagnosing children with heart defects, according to a new American Heart Association scientific statement.

3 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

McMaster receives new Canadian Cancer Society grants for groundbreaking research

Three cancer studies led by Hamilton researchers are among 52 new research projects worth close to $22 million announced by the Canadian Cancer Society.

3 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

Obesity during middle age may increase risk of developing dementia

According to a new study, being overweight or obese during middle age may increase the risk of certain dementias.

3 May 2011

Scientists discover new gene underlying angle-closure glaucoma

Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma.

3 May 2011

Statins can help reduce lung damage in severe abdominal sepsis

Statins may be best known for their ability to reduce cholesterol, but a research report appearing in the May 2011 issue of the Journal of Leukocyte Biology shows that these same drugs could also play a crucial role in the reduction of lung damage resulting from severe abdominal sepsis and infection.

3 May 2011

First cryoablation procedure using new mapping catheter performed at Baylor Heart and Vascular Hospital

Baylor Jack and Jane Hamilton Heart and Vascular Hospital today announced the first patient procedure in the U.S. using the Achieve Mapping Catheter, an intra-cardiac electrophysiology diagnostic catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation.

3 May 2011

SRS Medical announces pelvic health program for women

SRS Medical today announced the formation of Restore Continence™, a women's pelvic health program based on the use of a comprehensive suite of medical devices for diagnosing and treating urinary incontinence.

3 May 2011

Cyberonics initiates first implant of AspireSR product in epilepsy patients

Cyberonics, Inc., a global leader in epilepsy management, today announced the first implant of its AspireSR™ seizure response product on April 27, 2011.

3 May 2011

Research: Two-year-old children with autism have enlarged brains

In 2005, researchers from the University of North Carolina at Chapel Hill found that 2-year-old children with autism have brains up to 10 percent larger than children of the same age without autism.

3 May 2011

Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension

Merck, known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, Merck's investigational, preservative-free prostaglandin analogue ophthalmic solution, experienced a reduction in intraocular pressure comparable to patients taking twice-daily preservative-free timolol maleate, a beta-adrenergic antagonist.

3 May 2011

New non-invasive device can measure brain's precise temperature

Doctors have long sought a way to directly measure the brain's temperature without inserting a probe through the skull. Now researchers have developed a way to get the brain's precise temperature with a device the diameter of a poker-chip that rests on a patient's head, according to findings presented May 1 at the annual meeting of the Pediatric Academic Societies in Denver.

3 May 2011

Oragenics announces availability of oral care probiotics for children and adults

Florida-based biopharmaceutical company Oragenics, Inc. has announced that its oral care probiotics for children and adults will be available in Australia and New Zealand through an exclusive agreement with Australian Pharmaceutical Industries, owner of the Priceline pharmacy retail chain, and one of the leading service providers to the pharmacy industry.

3 May 2011

Aquaporin-4 plays a key role in brain inflammation

A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.

3 May 2011